Evidence map›Paper›PMID 42799079›Full record

ReviewACS omega2026

MXenes at the Immune Interface: A Perspective on Influence of Physicochemical Design in Immunomodulation.

Alireza Rafieerad, Leena Regi Saleth, Sanjiv Dhingra

Abstract readReview
In one paragraph

Review in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Alireza RafieeradUniversity of Manitoba Faculty of Health Sciences, Winnipeg, Manitoba R3E 3P4, Canada.
Leena Regi SalethUniversity of Manitoba Faculty of Health Sciences, Winnipeg, Manitoba R3E 3P4, Canada.
Sanjiv DhingraUniversity of Manitoba Faculty of Health Sciences, Winnipeg, Manitoba R3E 3P4, Canada.ORCID https://orcid.org/0000-0002-2664-7633

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MXenes are a recently discovered family of two-dimensional (2D) transition metal-based nanomaterials, known for their compositional diversity, exceptional tunability, structural versatility, and surface functionality. Beyond their well-established application in energy storage, MXenes have attracted growing interest for their promising role in regenerative biomedicine, particularly in antimicrobial and immune engineering applications. Recent studies, including contributions from our group, demonstrate that MXenes exhibit unique interactions with immune cells and associated immunosuppressive functions. Notably, MXene nanosheets and derived quantum dots can be tailored to modulate key immunosuppressive mechanisms, including the enhancement of regulatory T-cells (Tregs), reduction of proinflammatory cytokines, macrophages modulation and autophagy induction. These findings position MXenes as potential next-generation platform for immunomodulatory therapy, either as standalone agents or in combination with existing immunosuppressants. In this perspective, we systematically examine how physiochemical parameters including size, dimension, morphology, surface chemistry, and functionalization govern their interactions with innate and adaptive system. We highlight recent advances in MXene-mediated immunomodulation, paving a roadmap for further investigations, by identifying key knowledge gaps and translational challenges. We further outline future research directions necessary to bridge the divide between experimental studies, artificial intelligence (AI)-driven optimization/predictive approaches, and clinical applications of MXene-based immunotherapies.

Identifiers

PMID42799079
PMCPMC13613891

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.